Protalex Inc. | Balance Sheet

Fiscal year is June-May. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
2,457.00
1,614.80
928.30
444.20
487.40
555.40
Other Current Assets
42.30
45.30
56.40
55.70
107.20
74.40
Total Current Assets
2,499.40
1,660.10
984.70
499.90
594.60
629.80
Intangible Assets
6.50
5.40
4.40
3.40
2.40
1.40
Total Assets
2,505.80
1,665.50
989.10
503.30
597.00
631.20
ST Debt & Current Portion LT Debt
4,210.80
-
-
-
-
Accounts Payable
671.70
412.70
-
-
489.00
Other Current Liabilities
62.50
40.10
554.70
607.30
57.80
Total Current Liabilities
4,945.10
452.90
554.70
607.30
546.80
Long-Term Debt
6,000.00
9,000.00
12,524.40
16,319.40
20,299.40
Other Liabilities
57.60
397.20
498.60
932.90
1,490.40
Total Liabilities
11,002.70
9,850.00
13,577.60
17,859.50
22,336.60
Common Equity (Total)
8,496.90
8,184.50
12,588.50
17,356.20
21,739.60
Total Shareholders' Equity
8,496.90
8,184.50
12,588.50
17,356.20
21,739.60
Total Equity
8,496.90
8,184.50
12,588.50
17,356.20
21,739.60
Liabilities & Shareholders' Equity
2,505.80
1,665.50
989.10
503.30
597.00

About Protalex

View Profile
Address
131 Columbia Turnpike
Florham Park New Jersey 07932
United States
Employees -
Website http://www.protalex.com
Updated 07/08/2019
Protalex, Inc. is a development stage company which focuses on the development of a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases including rheumatoid arthritis. Its product includes PRTX-100, formulated with purified staphylococcal protein A, which is an immune modulating protein produced by bacteria. The company was founded by John E.